Abstract
There are expectations that stem cell therapy (SCT) will treat many currently untreatable diseases. The Internet is widely used by patients seeking information about new treatments, and hence, analyzing websites is a representative sample of the information available to the public. Our aim was to understand what information the public would find when searching for information on SCT on Google, as this would inform us on how lay people form their knowledge about SCT. We analyzed the content and information quality of the first 200 websites returned by a Google.com search on SCT. Most websites returned were from treatment centers (TC, 44%) followed by news and medical professional websites. The specialty most mentioned in non-TC websites was “neurological” (67%), followed by “cardiovascular” (42%), while the most frequent indication for which SCT is offered by TCs was musculoskeletal (89%) followed by neurological (47%). 45% of the centers specialized in treating one specialty, 10% two and 45% offered between three and 18 different specialties. Of the 78 treatment centers, 65% were in the USA, 23% in Asia and 8% in Latin America. None of the centers offered SCT based on embryonic cells. Health information quality (JAMA score, measuring trustworthiness) was lowest for TCs and commercial websites and highest for scientific journals and health portals. This study shows a disconnection between information about SCT and what is actually offered by TCs. The study also shows that TCs, potentially acting in a regulatory grey area, have a high visibility on the Internet.
Highlights
IntroductionScientific and lay discussion have linked stem cell therapy (SCT) to an extensive spectrum of conditions; it is a new and evolving area of medicine that is still largely being investigated
Stem cell therapy (SCT) offers much potential, and raises significant expectations
Specialties Mentioned by Websites or in Treatments Offered by treatment center (TC)
Summary
Scientific and lay discussion have linked SCT to an extensive spectrum of conditions; it is a new and evolving area of medicine that is still largely being investigated. The European Medicines Agency (EMA) approved its first SCT treatment in 2015 for the use of a corneal SC based therapy for treating corneal diseases (EMA, 2015). Both the FDA and EMA, as well as individual national level agencies, have policies in place for appropriate research and clinical translation of SCs (Bianco et al, 2013a)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
